Differential efficacy of human mesenchymal stem cells based on source of origin

Journal of Immunology

Volumn 193, Issue 9, 2014, Pages 4381-4390

  Collins, Erin ^a   Gu, Fei ^a,b   Qi, Maosong ^a   Molano, Ivan ^a   Ruiz, Phillip ^c   Sun, Lingyun ^b   Gilkeson, Gary S ^a,d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; COLONY STIMULATING FACTOR 1; COMPLEMENT COMPONENT C3; DOUBLE STRANDED DNA ANTIBODY; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 17; MONOCYTE CHEMOTACTIC PROTEIN 1; AUTACOID; CYTOKINE;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; COMPLEMENT DEPOSITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN DEPOSITION; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; UMBILICAL CORD; ADULT; ANIMAL; BIOSYNTHESIS; BONE MARROW; CELL DIFFERENTIATION; CYTOLOGY; DISEASE MODEL; DONOR; FEMALE; IMMUNOLOGY; IMMUNOPHENOTYPING; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MESENCHYMAL STROMA CELL; METABOLISM; MORTALITY; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; PATHOLOGY; PHENOTYPE; TREATMENT OUTCOME;

ADULT; ANIMALS; B-LYMPHOCYTES; BONE MARROW; CELL DIFFERENTIATION; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOPHENOTYPING; INFLAMMATION MEDIATORS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED MRL LPR; PHENOTYPE; T-LYMPHOCYTES; TISSUE DONORS; TREATMENT OUTCOME;

EID: 84908149278     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401636     Document Type: Article

References (41)

1. Klyushnenkova, E., J. D. Mosca, V. Zernetkina, M. K. Majumdar, K. J. Beggs, D. W. Simonetti, R. J. Deans, and K. R. McIntosh. 2005. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J. Biomed. Sci. 12: 47-57.
2. Corcione, A., F. Benvenuto, E. Ferretti, D. Giunti, V. Cappiello, F. Cazzanti, M. Risso, F. Gualandi, G. L. Mancardi, V. Pistoia, and A. Uccelli. 2006. Human mesenchymal stem cells modulate B-cell functions. Blood 107: 367-372.
3. Sotiropoulou, P. A., S. A. Perez, A. D. Gritzapis, C. N. Baxevanis, and M. Papamichail. 2006. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24: 74-85.
4. Beyth, S., Z. Borovsky, D. Mevorach, M. Liebergall, Z. Gazit, H. Aslan, E. Galun, and J. Rachmilewitz. 2005. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105: 2214-2219.
5. Ren, G., L. Zhang, X. Zhao, G. Xu, Y. Zhang, A. I. Roberts, R. C. Zhao, and Y. Shi. 2008. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2: 141-150.
6. Prevosto, C., M. Zancolli, P. Canevali, M. R. Zocchi, and A. Poggi. 2007. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 92: 881-888.
7. English, K., F. P. Barry, and B. P. Mahon. 2008. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol. Lett. 115: 50-58.
8. Wang, J., L. Liao, and J. Tan. 2011. Mesenchymal-stem-cell-based experimental and clinical trials: current status and open questions. Expert Opin. Biol. Ther. 11: 893-909.
9. Tsokos, G. C. 2011. Systemic lupus erythematosus. N. Engl. J. Med. 365: 2110-2121.
10. Nowling, T. K., and G. S. Gilkeson. 2011. Mechanisms of tissue injury in lupus nephritis. Arthritis Res. Ther. 13: 250-259.
11. Lo, M. S., and G. C. Tsokos. 2012. Treatment of systemic lupus erythematosus: new advances in targeted therapy. Ann. N. Y. Acad. Sci. 1247: 138-152.
12. Lichtman, E. I., S. M. Helfgott, and M. A. Kriegel. 2012. Emerging therapies for systemic lupus erythematosus - focus on targeting interferon-alpha. Clin. Immunol. 143: 210-221.
13. Gu, F., I. Molano, P. Ruiz, L. Sun, and G. S. Gilkeson. 2012. Differential effect of allogeneic versus syngeneic mesenchymal stem cell transplantation in MRL/lpr and (NZB/NZW)F1 mice. Clin. Immunol. 145: 142-152.
14. Sun, L., K. Akiyama, H. Zhang, T. Yamaza, Y. Hou, S. Zhao, T. Xu, A. Le, and S. Shi. 2009. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 27: 1421-1432.
15. Ji, S., Q. Guo, Y. Han, G. Tan, Y. Luo, and F. Zeng. 2012. Mesenchymal stem cell transplantation inhibits abnormal activation of Akt/GSK3β signaling pathway in T cells from systemic lupus erythematosus mice. Cell. Physiol. Biochem. 29: 705-712.
16. Gu, Z., K. Akiyama, X. Ma, H. Zhang, X. Feng, G. Yao, Y. Hou, L. Lu, G. S. Gilkeson, R. M. Silver, et al. 2010. Transplantation of umbilical cord mesenchymal stem cells alleviates lupus nephritis in MRL/lpr mice. Lupus. 19: 1502-1514.
17. Youd, M., C. Blickarz, L. Woodworth, T. Touzjian, A. Edling, J. Tedstone, M. Ruzek, R. Tubo, J. Kaplan, and T. Lodie. 2010. Allogeneic mesenchymal stem cells do not protect NZB×NZW F1 mice from developing lupus disease. Clin. Exp. Immunol. 161: 176-186.
18. Schena, F., C. Gambini, A. Gregorio, M. Mosconi, D. Reverberi, M. Gattorno, S. Casazza, A. Uccelli, L. Moretta, A. Martini, and E. Traggiai. 2010. Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis Rheum. 62: 2776-2786.
19. Chang, J.-W., S.-P. Hung, H.-H. Wu, W.-M. Wu, A.-H. Yang, H.-L. Tsai, L.-Y. Yang, and O. K. Lee. 2011. Therapeutic effects of umbilical cord blood-derived mesenchymal stem cell transplantation in experimental lupus nephritis. Cell Transplant. 20: 245-257.
20. Choi, E. W., I. S. Shin, S. Y. Park, J. H. Park, J. S. Kim, E. J. Yoon, S. K. Kang, J. C. Ra, and S. H. Hong. 2012. Reversal of serologic, immunologic, and histologic dysfunction in mice with systemic lupus erythematosus by long-term serial adipose tissue-derived mesenchymal stem cell transplantation. Arthritis Rheum. 64: 243-253.
21. Wang, D., H. Zhang, J. Liang, X. Li, X. Feng, H. Wang, B. Hua, B. Liu, L. Lu, G. S. Gilkeson, et al. 2012. Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years experience. Cell Transplant. 10.3727/096368912X658719.
22. Sun, L. Y., H. Y. Zhang, X. B. Feng, Y. Y. Hou, L. W. Lu, and L. M. Fan. 2007. Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 16: 121-128.
23. Carrion, F., E. Nova, C. Ruiz, F. Diaz, C. Inostroza, D. Rojo, G. Mönckeberg, and F. E. Figueroa. 2010. Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus 19: 317-322.
24. Sun, L., D. Wang, J. Liang, H. Zhang, X. Feng, H. Wang, B. Hua, B. Liu, S. Ye, X. Hu, et al. 2010. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 62: 2467-2475.
25. Dominici, M., K. Le Blanc, I. Mueller, I. Slaper-Cortenbach, F. Marini, D. Krause, R. Deans, A. Keating, Dj. Prockop, and E. Horwitz. 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317.
26. Pittenger, M. F., A. M. Mackay, S. C. Beck, R. K. Jaiswal, R. Douglas, J. D. Mosca, M. A. Moorman, D. W. Simonetti, S. Craig, and D. R. Marshak. 1999. Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147.
27. Yang, J., Y. Chu, X. Yang, D. Gao, L. Zhu, X. Yang, L. Wan, and M. Li. 2009. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 60: 1472-1483.
28. Menke, J., W. A. Rabacal, K. T. Byrne, Y. Iwata, M. M. Schwartz, E. R. Stanley, A. Schwarting, and V. R. Kelley. 2009. Circulating CSF-1 promotes monocyte and macrophage phenotypes that enhance lupus nephritis. J. Am. Soc. Nephrol. 20: 2581-2592.
29. Singh, R. G., S. Usha, S. S. Rathore, S. K. Behura, and N. K. Singh. 2012. Urinary MCP-1 as diagnostic and prognostic marker in patients with lupus nephritis flare. Lupus 21: 1214-1218.
30. Chan, R. W.-Y., L.-S. Tam, E. K.-M. Li, F. M.-M. Lai, K.-M. Chow, K.-B. Lai, P. K.-T. Li, and C.-C. Szeto. 2003. Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum. 48: 1326-1331.
31. Guo, Z., C. Zheng, Z. Chen, D. Gu, W. Du, J. Ge, Z. Han, and R. Yang. 2009. Fetal BM-derived mesenchymal stem cells promote the expansion of human Th17 cells, but inhibit the production of Th1 cells. Eur. J. Immunol. 39: 2840-2849.
32. Traggiai, E., S. Volpi, F. Schena, M. Gattorno, F. Ferlito, L. Moretta, and A. Martini. 2008. Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 26: 562-569.
33. Ren, G., J. Su, L. Zhang, X. Zhao, W. Ling, A. L'huillie, J. Zhang, Y. Lu, A. I. Roberts, W. Ji, et al. 2009. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 27: 1954-1962.
34. Chinnadurai, R., I. B. Copland, S. R. Patel, and J. Galipeau. 2014. IDO-independent suppression of T cell effector function by IFN-γ-licensed human mesenchymal stromal cells. J. Immunol. 192: 1491-1501.
35. Wang, D., X. Feng, L. Lu, J. E. Konkel, H. Zhang, Z. Chen, X. Li, X. Gao, L. Lu, S. Shi, et al. 2014. A CD8 T cell-indoleamine 2,3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus. Arthritis Rheumatol. 66: 2234-2245. 10.1002/art.38674
36. Ni, X., Y. Q. Jia, W. T. Meng, L. Zhong, and Y. Zeng. 2009. Expression of B7-H1 molecule on human bone marrow mesenchymal stem cells and its effects on T lymphocyte proliferation. Zhongguo Shi Yan Xue Ye Xue Za Zhi 17: 990-993.
37. Meisel, R., A. Zibert, M. Laryea, U. Göbel, W. Däubener, and D. Dilloo. 2004. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103: 4619-4621.
38. Ryan, J. M., F. Barry, J. M. Murphy, and B. P. Mahon. 2007. Interferon-γ does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin. Exp. Immunol. 149: 353-363.
39. Ho, A., L. S. Magder, S. G. Barr, and M. Petri. 2001. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum. 44: 2342-2349.
40. Sato, K., K. Ozaki, I. Oh, A. Meguro, K. Hatanaka, T. Nagai, K. Muroi, and K. Ozawa. 2007. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109: 228-234.
41. Polchert, D., J. Sobinsky, G. Douglas, M. Kidd, A. Moadsiri, E. Reina, K. Genrich, S. Mehrotra, S. Setty, B. Smith, and A. Bartholomew. 2008. IFN-γ activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur. J. Immunol. 38: 1745-1755.